183 related articles for article (PubMed ID: 29895933)
1. Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.
Wang M; Fan W; Ye M; Tian C; Zhao L; Wang J; Han W; Yang W; Gu C; Li M; Zhang Z; Wang Y; Zhang H; Meng Y
Sci Rep; 2018 Jun; 8(1):8990. PubMed ID: 29895933
[TBL] [Abstract][Full Text] [Related]
2. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
Alborelli I; Bratic Hench I; Chijioke O; Prince SS; Bubendorf L; Leuenberger LP; Tolnay M; Leonards K; Quagliata L; Jermann P; Matter MS
Lung Cancer; 2020 Nov; 149():84-89. PubMed ID: 32980613
[TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
4. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
[TBL] [Abstract][Full Text] [Related]
5. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
[TBL] [Abstract][Full Text] [Related]
7. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
[TBL] [Abstract][Full Text] [Related]
8. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
10. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
11. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
12. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
[TBL] [Abstract][Full Text] [Related]
13. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
14. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
Patel RR; Ramkissoon SH; Ross J; Weintraub L
Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
Akahane T; Kitazono I; Yanazume S; Kamio M; Togami S; Sakamoto I; Nohara S; Yokoyama S; Kobayashi H; Hiraki T; Suzuki S; Ueno S; Tanimoto A
BMC Med Genomics; 2020 Jul; 13(1):101. PubMed ID: 32652986
[TBL] [Abstract][Full Text] [Related]
19. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
Liang X; Li Q; Xu B; Hu S; Wang Q; Li Y; Zong Y; Zhang S; Li C
Int J Clin Oncol; 2019 Sep; 24(9):1061-1068. PubMed ID: 31065835
[TBL] [Abstract][Full Text] [Related]
20. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]